Core Scientific (CORZR) Current Deferred Revenue (2021 - 2026)

Core Scientific's Current Deferred Revenue history runs 6 years deep, the most recent figure standing at $654.2 million for Q1 2026.

• In Q1 2026, Current Deferred Revenue rose 974.26% year-over-year to $654.2 million; the TTM figure through Mar 2026 stood at $654.2 million (up 974.26% YoY), while the FY2025 annual figure was $555.9 million, up 2965.24% from the prior year.
• Current Deferred Revenue came in at $654.2 million for Q1 2026 at Core Scientific, up from $555.9 million in the prior quarter.
• In the past five years, Current Deferred Revenue ranged from a high of $654.2 million in Q1 2026 to a low of $2.5 million in Q3 2025.
• A 5-year average of $142.5 million and a median of $69.3 million in 2022 frame the typical range for Current Deferred Revenue.
• Across the five-year window, Current Deferred Revenue tumbled 87.35% in 2023 and surged 2965.24% in 2025, its largest moves.
• Core Scientific's Current Deferred Revenue stood at $77.7 million in 2022, then sank by 87.35% to $9.8 million in 2023, then soared by 84.48% to $18.1 million in 2024, then soared by 2965.24% to $555.9 million in 2025, then gained by 17.7% to $654.2 million in 2026.
• According to Business Quant data, Current Deferred Revenue over the past three periods registered $654.2 million, $555.9 million, and $2.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison